Skip to main
SRIMF

StemRIM Inc (SRIMF)


$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy StemRIM Inc (SRIMF) Stock

About StemRIM Inc (SRIMF)

StemRIM, Inc. engages in the research and development of regeneration inducing medicine. It deals with areas of disease and pipelines, autologous cell sampling devices for medical treatment, autologous stem cell collection, stem cell gene therapy and others. The company was founded by Katsuto Tamai on October 30, 2006 and is headquartered in Ibaraki, Japan.
Market cap—
Today's volume—
Revenue (TTM)—
Avg. daily volume—
EBITDA (TTM)-$12.61M
Open—
Price / earnings ratio—
Today's range—
Debt / equity—
52 week range—
5 year debt / equity—
Beta (LTM)—
Interest coverage—
Dividend & yield— (—)
Current ratio70.97x
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy SRIMF stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in SRIMF stock

    Navigate to the Explore page. Then, type SRIMF into the search bar. When you see SRIMF stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased SRIMF stock in your portfolio alongside the rest of your stocks, ETFs, crypto, bonds, options, and your high-yield cash account––all in one place on Public.

Buy StemRIM Inc (SRIMF) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.